Avexitide
Medium EvidenceA first-in-class once-daily injectable GLP-1 receptor ANTAGONIST (exendin 9-39) from Amylyx for hyperinsulinemic hypoglycemia. The mirror image of GLP-1 agonists like semaglutide, it blocks GLP-1 to stop the insulin surges that cause post-bariatric hypoglycemia. Phase 3 LUCIDITY completed enrollment March 2026 with topline data expected Q3 2026.
What It Is
Avexitide is a first-in-class, once-daily injectable GLP-1 receptor ANTAGONIST being developed by Amylyx Pharmaceuticals for hyperinsulinemic hypoglycemia — most advanced in post-bariatric hypoglycemia (PBH) and also studied in congenital hyperinsulinism (HI). It is the mirror image of the blockbuster GLP-1 agonist class (semaglutide, tirzepatide, orforglipron): where those drugs activate the GLP-1 receptor to boost insulin and curb appetite, avexitide BLOCKS it. Chemically, avexitide is exendin (9-39), a synthetic 31-amino-acid peptide fragment of exendin-4 (the same lizard-derived peptide that inspired exenatide), and it is a potent, selective competitive GLP-1 receptor antagonist. By blocking GLP-1 signaling on pancreatic beta cells, it dampens the exaggerated, glucose-independent insulin surges that cause dangerous post-meal blood-sugar crashes. Post-bariatric hypoglycemia is a debilitating complication of gastric bypass (Roux-en-Y, RYGB) in which rapid nutrient delivery drives excessive GLP-1 and insulin release, producing severe hypoglycemia; there is currently no FDA-approved therapy. Avexitide originated at Eiger BioPharmaceuticals, which took it through five clinical trials; after Eiger entered Chapter 11 bankruptcy in April 2024, Amylyx acquired the Phase 3-ready asset for about $35.1 million in July 2024, pivoting the company into the metabolic space following the discontinuation of its ALS drug. In a Phase 2b PBH trial, avexitide 90 mg once daily produced a 64% least-squares-mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events. The pivotal Phase 3 LUCIDITY trial (NCT06747693) enrolled 78 adults with PBH after RYGB in a 16-week, randomized, double-blind, placebo-controlled design; its FDA-agreed primary endpoint is the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. LUCIDITY completed enrollment in March 2026, and Amylyx expects topline data in the third quarter of 2026, with a potential commercial launch in 2027 if approved. Avexitide holds FDA Breakthrough Therapy Designation for both post-bariatric hypoglycemia (granted to Amylyx in 2024) and congenital hyperinsulinism (originally granted to Eiger in 2021), plus Orphan Drug Designation. It is not approved for any use anywhere, and — as an injectable clinical-stage peptide — is not a supplement or research chemical.
Regulatory Status
FDA Breakthrough Therapy Designation for post-bariatric hypoglycemia (2024) and congenital hyperinsulinism (2021), plus Orphan Drug Designation. Pivotal Phase 3 LUCIDITY trial in PBH completed enrollment (78 participants) in March 2026; Amylyx expects topline data in Q3 2026 and, if positive, a potential U.S. launch in 2027. Not approved for any indication anywhere.
Effective: March 2026
View FDA SourceWhy Researchers Study It
Avexitide is the leading clinical example of a counterintuitive idea: BLOCKING the GLP-1 receptor rather than activating it. In hyperinsulinemic hypoglycemia — post-bariatric hypoglycemia and congenital hyperinsulinism — the problem is too much insulin at the wrong time, and GLP-1 amplifies it. Researchers study avexitide as a mechanistically precise, first-in-class therapy for conditions with no approved treatment, and as living proof that the GLP-1 axis can be tuned in both directions. Its Breakthrough Therapy Designations and imminent Phase 3 readout make it one of the most closely watched rare-metabolic peptides of 2026.
Proposed Mechanisms
- Competitive, selective antagonism of the GLP-1 receptor by exendin (9-39), a 31-amino-acid exendin-4 fragment
- Blunts glucose-independent, GLP-1-driven insulin secretion from pancreatic beta cells
- Raises nadir blood glucose and reduces the frequency and severity of Level 2 and Level 3 hypoglycemic events
- Targets the excessive post-meal GLP-1 surge that follows Roux-en-Y gastric bypass in post-bariatric hypoglycemia
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 2b (post-bariatric hypoglycemia) | Adults with PBH after RYGB — dose-ranging | Avexitide 90 mg once daily produced a 64% least-squares-mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus baseline | Source |
| Phase 3 (LUCIDITY, PBH, NCT06747693) | 78 adults with post-bariatric hypoglycemia after RYGB — 16-week randomized, double-blind, placebo-controlled | Fully enrolled March 2026; FDA-agreed primary endpoint is reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16; topline data expected Q3 2026 | Source |
| Phase 2 (congenital hyperinsulinism) | Children and adolescents with congenital HI (three completed Phase 2 studies, 39 participants total) | Exendin (9-39) reduced hyperinsulinemic hypoglycemia and raised fasting and post-meal glucose, supporting Breakthrough Therapy Designation in congenital HI | Source |
Commonly Discussed Benefits
Researching Avexitide? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Investigational — not approved for any use anywhere
- Pivotal Phase 3 LUCIDITY topline data are not yet reported (expected Q3 2026); efficacy to date is from earlier-phase trials
- A GLP-1 receptor ANTAGONIST — opposite in mechanism to GLP-1 agonists; it is NOT a weight-loss drug and is not interchangeable with semaglutide or tirzepatide
- Being developed for rare hyperinsulinemic hypoglycemia disorders under specialist care, not for general metabolic or performance use
- Any 'avexitide' or 'exendin 9-39' offered by a vendor is unverified — this is a clinical-stage pharmaceutical, not a supplement or research chemical
Comparisons
See how Avexitide compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Amylyx Pharmaceuticals — Completion of Enrollment in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia PubMed
- [2] Amylyx Pharmaceuticals — Acquisition of Phase 3-ready GLP-1 Receptor Antagonist Avexitide with FDA Breakthrough Therapy Designation (July 2024) PubMed
- [3] Amylyx Pharmaceuticals — First Quarter 2026 Financial Results (avexitide program update) PubMed
- [4] Exendin (9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism — Diabetes Care PubMed
- [5] LUCIDITY (Avexitide in Post-Bariatric Hypoglycemia) — ClinicalTrials.gov NCT06747693 PubMed
Keep researching in the app
- Log Avexitide to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Orforglipron
High EvidenceThe first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions.
Setmelanotide
High EvidenceA once-daily subcutaneous cyclic octapeptide melanocortin-4 receptor (MC4R) agonist, FDA-approved for several rare genetic and acquired forms of obesity that act through the leptin-melanocortin pathway.